A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
TuHURA Biosciences, Inc.
Alpha Tau Medical LTD.
Iovance Biotherapeutics, Inc.
Institute of Oncology Ljubljana
Memorial Sloan Kettering Cancer Center
Intergruppo Melanoma Italiano
Medicenna Therapeutics, Inc.